KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medpace Holdings (MEDP) Receivables (2016 - 2025)

Medpace Holdings (MEDP) has disclosed Receivables for 11 consecutive years, with $402.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 35.64% year-over-year to $402.1 million, compared with a TTM value of $402.1 million through Dec 2025, up 35.64%, and an annual FY2025 reading of $402.1 million, up 35.64% over the prior year.
  • Receivables was $402.1 million for Q4 2025 at Medpace Holdings, up from $383.8 million in the prior quarter.
  • Across five years, Receivables topped out at $402.1 million in Q4 2025 and bottomed at $160.3 million in Q1 2021.
  • Average Receivables over 5 years is $285.2 million, with a median of $295.1 million recorded in 2022.
  • The sharpest move saw Receivables skyrocketed 64.88% in 2022, then decreased 3.07% in 2024.
  • Year by year, Receivables stood at $222.5 million in 2021, then soared by 32.03% to $293.8 million in 2022, then rose by 1.56% to $298.4 million in 2023, then decreased by 0.66% to $296.4 million in 2024, then soared by 35.64% to $402.1 million in 2025.
  • Business Quant data shows Receivables for MEDP at $402.1 million in Q4 2025, $383.8 million in Q3 2025, and $377.9 million in Q2 2025.